Is the TB-500 fragment the same as full thymosin β-4?

No. It is a short piece built around the actin-binding motif. The full clinically studied molecule is much longer, and the two should not be treated as equivalent.

Why does this distinction matter?

Because most "TB-500" marketing cites data from full thymosin β-4 while the product in the vial may be only the fragment — so the evidence used to sell it may not apply to what you receive.

In vitroResearch compound

TB-500 Fragment

Also known as: Tβ4 fragment, Actin-binding domain peptide, LKKTETQ-containing fragment

The short, actin-binding fragment that most "TB-500" products actually contain — frequently confused with the full thymosin β-4 molecule used in clinical research.

Injectable

Last updated June 19, 2026

Mechanism

Full thymosin β-4 (Tβ4) is a 43–amino-acid peptide. Its actin-binding activity is concentrated in a short internal sequence (centered on the motif LKKTETQ). Many "TB-500" research products supply only a fragment built around this motif rather than the complete molecule. The fragment retains some actin-regulating, cell-migration–promoting activity in the lab, but it is not identical to the full peptide that went through preclinical and early human studies.

What the research shows

This is the most evidence-limited profile in the cluster, and that is the point of including it: the fragment commonly sold as "TB-500" is not the same molecule as the clinically studied full thymosin β-4, yet the two are routinely marketed interchangeably. Direct, peer-reviewed studies of the standalone consumer fragment are scarce; most claims borrow data from full Tβ4. Buyers frequently do not know which they are getting. We grade the fragment's own evidence as in-vitro at best and flag the labeling confusion as a primary risk.

Evidence grade: In vitro — Cell- or tissue-culture evidence only — far from clinical proof.

Benefits studied

Actin-binding and cell-migration activity attributable to the LKKTETQ motif in vitro
Repair-related signals extrapolated from full thymosin β-4 research

Risks & unknowns

Routinely sold as "TB-500" but is not the full clinically studied thymosin β-4
Very little direct peer-reviewed evidence for the standalone fragment
Label/identity confusion means buyers often cannot tell what they purchased
No human efficacy or long-term safety data; banned in sport by WADA

Regulatory status

Research compound. Sold "for research use only" — not approved for human consumption.

Goals studied: Tendon & ligament repair, Muscle recovery

FAQ

Is the TB-500 fragment the same as full thymosin β-4?: No. It is a short piece built around the actin-binding motif. The full clinically studied molecule is much longer, and the two should not be treated as equivalent.
Why does this distinction matter?: Because most "TB-500" marketing cites data from full thymosin β-4 while the product in the vial may be only the fragment — so the evidence used to sell it may not apply to what you receive.

Sources

[1]
Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues
Goldstein AL, Hannappel E, Kleinman HK · Trends in Molecular Medicine · 2005 · PMID 16099219 · model: in-vitro
Revue expliquant comment ce peptide séquestreur d'actine devient un signal de réparation extracellulaire lorsqu'il est libéré après une lésion.